Skip to main content

Formulation Compatibility of Myristyl Nicotinate With Drugs Used To Treat Dermatological Conditions

A number of dermatology conditions including skin photodamage, atopic dermatitis, and rosacea involve skin barrier impairment and first line therapies for these conditions including retinoids and steroids further impair skin barrier function.

We have evaluated the compatibility of myristyl nicotinate, an agent that enhances skin barrier function, with drugs used to treat conditions where skin barrier impairment is present including photodamage (retinoic acid), atopic dermatitis (hydrocortisone, triamcinolone acetonide), rosacea (metronidazole), and seborrheic dermatitis (ketoconazole).

Myristyl nicotinate was found to be compatible with each of the drugs examined when formulated together and also was shown to be photocompatible with retinoic acid. Our results suggest that the combination of myristyl nicotinate with these drugs is a feasible therapeutic development strategy.


"Formulation compatibility of myristyl nicotinate with drugs used to treat dermatological conditions involving an impaired skin barrier"
Tashtoush BM, Kim H, Jacobson EL, Jacobson MK
Drug Dev Ind Pharm. 2007 Nov ; 33(11): 1176-82 (Hubmed.org)



Highlight :
Treatment Of Rosacea | Acne Rosacea Antibiotic | Acne Rosacea | Rosacea Creams

Popular posts from this blog

Prevalence Of And Associated Factors For Dry Eye In A Spanish adult population

To estimate the prevalence of dry eye and to investigate its relationship with lifestyle and systemic factors in a general adult population in north-western Spain. METHODS: A dry eye questionnaire was administered and objective tests were performed in 654 individuals [mean age (Standard deviation): 63.6 (14.4) years, range: 40-96, 37.2% males]. Subjects were considered symptomatic when one or more of the symptoms of the questionnaire were present often or all the time. Schirmer test or= 3 and fluorescein staining >or= 1 were considered indicative of signs. Dry eye was defined as the simultaneous presence of symptoms and at least one sign. A design based analysis was performed and all calculations were weighted to give unbiased estimates. RESULTS: Dry eye prevalence was 11.0% (95%confidence interval [CI] 8.6-13.3). Dry eye was found to be more frequent in women (11.9%, 95%CI 8.8-15.1) than in men (9.0%, 95%CI 5.3-12.6), and was significantly associated with aging (p autoimmune diseas...
Read more

Treatments For Rosacea

The specific treatments for rosacea is determined by your physician based on: Your age, general health and medical history. How advanced is the eruption. Tolerance to specific medications, procedures or therapies. Their expectations for the trajectory of the eruption. Your opinion or preference. Treatments for rosacea may include : Modifications to diet Antibiotics. Cortisone ointment. Laser surgery Use sunscreen with a sun protection factor Currently there are several treatments for rosacea are used, depending on the events that it has. At the initial stage, to prevent the dilation of blood vessels and the consequent need to avoid red hot environments, exposure to sunlight, extreme changes in temperature and food hot or too much seasoning. When pustules that resemble pimples, prescribed oral antibiotics such as tetracycline. Another alternative treatments for rosacea is the topical antibiotics such as metronidazole. Also is using retinoids, which regulate the sebum production of the ...
Read more

ATPgammaS enhances the production of inflammatory mediators

Adenosine 5'-triphosphate (ATP) affects multiple intra- and extracellular processes, including vascular tone and immune responses. Microvascular endothelial cells (EC) play a central role in inflammation by recruitment of inflammatory cells from blood to tissues. We hypothesized that ATP (secreted by neurons and/or released after perturbation of cutaneous cells) may influence secretion of inflammatory messengers by dermal microvascular EC through actions on purinergic P2 receptors. Addition of the hydrolysis-resistant ATP analogue, adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), to subconfluent cultures of the human microvascular endothelial cell-1 (HMEC-1) cell line led to a dose- and time-dependent increase in release of IL-6, IL-8, monocyte chemoattractant protein-1, and growth-regulated oncogene alpha. Both ATPgammaS-induced release and basal production of these proteins were significantly inhibited by the purinergic antagonists pyridoxal-5'-phosphate-6-azophenyl-2...
Read more